NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-MH-18-073 from the NIH Guide for Grants and Contracts
Notice NOT-DC-19-002 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-011 from the NIH Guide for Grants and Contracts
Notice NOT-AG-18-045 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DE-19-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Funding Opportunity RFA-DE-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Funding Opportunity RFA-CA-19-005 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote the creation of developing research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Developing Centers (under this FOA) and P50 Advanced Centers (companion RFA-CA-19-006).
Funding Opportunity RFA-CA-19-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote the development of advanced research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing, and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Advanced Centers (under this FOA) and P50 Developing Centers (companion RFA-CA-19-005).
Notice NOT-CA-19-010 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-006 from the NIH Guide for Grants and Contracts
Notice NOT-AG-18-034 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-19-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and clinical infectious diseases.
Funding Opportunity PA-19-066 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.
Funding Opportunity PA-19-067 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.
Funding Opportunity PA-19-065 from the NIH Guide for Grants and Contracts. The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop virtual coaches by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate).
Funding Opportunity RFA-AI-18-053 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) will support basic science research to address outstanding questions in HIV latency and persistence by leveraging state-of-the-art single-cell multi-omics approaches. The goal is to interrogate HIV persistence with high molecular detail and resolution to better understand HIV persistence at the single-cell level. Emphasis will be on multi-omics or multiplex approaches integrating cutting-edge single-cell analysis technologies.
Notice NOT-OD-19-030 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-064 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); and 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service. It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).
Funding Opportunity RFA-DK-18-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Diabetic Foot Consortium (DFC) for clinical research on diabetic foot ulcers. The first studies will validate biomarkers that predict healing or response to therapy and assess infection or recurrence risk. Future research may involve clinical trials and studies on the pathophysiology of diabetic foot ulcers. Given the clinical complexity of diabetic wound healing, the applicant must have experience serving as the DCC on clinical studies of diabetic foot ulcers. The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.
Funding Opportunity PAR-19-061 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts aimed towards commercial product development in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports genomics research developing innovative analytical and computational commercial products, methodologies, and approaches, early stage development of commercial tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.